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Abstract
Background: Acute Myeloid Leukemia (AML) is characterized by various cytogenetic and molecular abnormalities.
Detection of these abnormalities is important in the risk-classification of patients but requires laborious
experimentation. Various studies showed that gene expression profiles (GEP), and the gene signatures derived from
GEP, can be used for the prediction of subtypes in AML. Similarly, successful prediction was also achieved by
exploiting DNA-methylation profiles (DMP). There are, however, no studies that compared classification accuracy
and performance between GEP and DMP, neither are there studies that integrated both types of data to determine
whether predictive power can be improved.
Approach: Here, we used 344 well-characterized AML samples for which both gene expression and DNA-
methylation profiles are available. We created three different classification strategies including early, late and no
integration of these datasets and used them to predict AML subtypes using a logistic regression model with Lasso
regularization.
Results: We illustrate that both gene expression and DNA-methylation profiles contain distinct patterns that
contribute to discriminating AML subtypes and that an integration strategy can exploit these patterns to achieve
synergy between both data types. We show that concatenation of features from both data sets, i.e. early
integration, improves the predictive power compared to classifiers trained on GEP or DMP alone. A more
sophisticated strategy, i.e. the late integration strategy, employs a two-layer classifier which outperforms the early
integration strategy.
Conclusion: We demonstrate that prediction of known cytogenetic and molecular abnormalities in AML can be
further improved by integrating GEP and DMP profiles.
Introduction
Over the last decade, microarray technologies that mea-
sures gene expression profiles (GEP) proved to be effective
for the detection of biomarkers for diagnosis and prog-
nosis of disease and for helping with the determination of
drug treatment [1]. More recently, microarray-based GEP
is emerging as a predictive tool to further refine risk strati-
fication in patients with myeloma [2]. In this study, we
focused on patients with Acute Myeloid Leukemia (AML).
AML is a heterogeneous disease for which groups of
patients can be identified with common cytogenetic or
molecular abnormality (denoted as subtypes) [3]. Many
abnormalities in AML, such as in gene fms-like tyro-sine
kinase 3 (FLT3), nucleophosmin (NPM1 ) or CCAAT
enhancer binding protein alpha (CEBPA), are nowadays
used for risk-classification of patients [4,5]. Currently,
laborious diagnostic techniques are used to detect these
cytogenetical or molecular abnormalities, such as direct
Sanger sequencing on patients with an abnormal denatur-
ing high-performance liquid chromatography profile
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(dHPLC) [6]. Alternatively, AML subtypes can also be
determined based on predictive gene signatures derived
using classification models from a training dataset with
known subtypes. Therefore, a better classification per-
formance and robust gene signature is highly relevant
for future clinical practice. Although it has already
been demonstrated that some subtypes can be pre-
dicted very well using GEP, e.g. t(8;21), t(15;17), inv
(16), or CEBPAdouble-mutant [7], challenges lie ahead for
subtypes such as patients carrying abnormalities in
FLT3, NPM1, or with certain chromosomal abnormal-
ities (3q, 11q23, 5q, 7q) [8], where it is much more dif-
ficult to predict these accurately. This is an indication
that gene expression profiles do not contain features
that are sufficiently discriminative to distinguish those
groups of patients from the others.
Besides gene expression profiles, DNA-methylation
profiles (DMP) also provide insight into the pathology
of Acute Myeloid Leukemia (AML) [9]. In particular t
(8;21), t(15;17), and inv(16) leukemia entities are asso-
ciated with specific methylation profiles, and four epige-
netic distinct forms of AML with NPM1 mutations are
detected [9]. This suggests that a number of genes may
be regulated at the methylation level and consequently
could be included in predictive gene signatures. Another
example is CCAAT-enhancer binding protein alpha
CEBPA, which is an important transcription factor in
AML and a mutation (e.g. double mutation in CEBPA)
can cause a selective block in differentiation, a hallmark
of AML [10,11]. However, there are patients that are
highly similar to the CEBPAdouble-mutant cases, but do
not harbour this mutation. Follow-up experimentation
showed that these patients contained a unique epige-
netic feature, i.e. CEBPA is silenced by DNA hyper-
methylation (denoted as the CEBPAsilenced subtype) [12].
Thus, by only looking at mRNA expression levels, simi-
lar expression patterns for different phenotypes can
arise. However, if epigenetic regulation is incorporated,
e.g. the promoter methylation of genes is taken into
account while deriving predictive gene signatures, such
underlying patterns may be disclosed.
The combination of GEP with other data types mea-
sured in the same sample is not frequently available. To
derive more reliable and robust gene signatures and
improve classification performance many methods have
therefore been developed that integrate GEP with prior
knowledge. Some examples include integration with
protein-protein networks [13,14], protein sequences simi-
larities [15], pathways, gene ontology or other functional
groups of genes [16]. Although such additional data can
approximate the functional roles of genes, it is more
powerful to include additional measurements on the same
set of samples to directly probe the relevance of biological
processes within these samples. This is demonstrated in
studies where multiple data sets are integrated to improve
classification power, such as integration of GEP with clini-
cal data [17], GEP with single-nucleotide polymorphisms
[18], or GEP with Copy Number Variations and other clin-
ical information [19].
We hypothesize that the prediction of AML subtypes
can be improved by combining gene expression and
DNA-methylation profiles, as it has previously been
shown that DNA-methytlation patterns contain comple-
mentary information on top of the gene expression pat-
terns in an unsupervised analysis. For example, it has
been shown that integrating GEP and DMP revealed
two unique, and clinically relevant AML patient-clusters
that could not be discovered when using either GEP or
DMP alone [20].
While both gene expression and DNA-methylation pro-
files have been used to gain insight in AML [3,9], there
are, to our knowledge, currently no studies that describe
how they should be integrated to exploit possible synergies
between these data types for prediction purposes. In fact
there are many ways in which multiple measurements in
the same sample can be integrated. In this study we pro-
pose and investigate two integration strategies, early and
late integration, and compare the classification perfor-
mance with that obtained using the two data types sepa-
rately, i.e. no integration.
Results
Gene expression profiles outperform DNA-methylation
profiles
We compared the predictive power for AML subtypes
by independently assessing the predictive power of GEP
and DMP. We found that the use of mRNA expression
profiles equals or outperforms the DNA-methylation
profiles in classification accuracy (F-score, Figure 1A
and Additional file 1: Table S1) for all subtypes. The
best results for DMP are obtained for the subtypes, inv
(16), CEBPAdouble-mutation, and CEBPAsilenced. However,
the accuracy (F-score, 0.9455, 0.9556, and 0.6667 respec-
tively) and classification performance (AUC, 0.9995, 1,
and 0.9955 respectively, Figure 1B and Additional file 1:
Table S1) is similar to those obtained using GEP. Thus,
in terms of predictive power (accuracy or performance) it
does not matter whether GEP or DMP is used to classify
the latter three subtypes. On the other hand, the results
obtained with the global test clearly show that features
from GEP are more significantly associated with the sub-
types than features from DMP. For instance, inv(16)
(PGEP = 8.95E - 06, PDMP = 0.014), CEBPA
double-mutation
(PGEP = 8.21E - 06, PDMP = 0.0053), and CEBPA
silenced
(PGEP = 1.11E - 05, PDMP = 1.5E - 04). This trend is also
apparent for the other subtypes (Figure 1C andAdditional
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file 1: Table S1). Although the AUC shows minimal dif-
ference between GEP and DMP over all AML subtypes,
the GEP features are more discriminative.
Early integration improves (or equals) predictive power
The early integration strategy improves (or equals) the
classification accuracy for all 15 subtypes compared to
DMP, and for 8 out of 15 subtypes for GEP (Figure 1A
andAdditional file 1: Table S1). On the other hand, the
performance improves (or equals) for 10 out of 15 sub-
types compared to GEP and 12 out of 15 subtypes for
DMP alone. This demonstrates that integrating methyla-
tion and expression profiles is useful for the prediction
of the leukemia subtypes. This is especially the case for
the recently identified CEBPAsilenced subtype for which it
is known that it contains a unique epigenetic signature
[12]. The global test revealed that the use of the com-
bined feature space results in increased associations for
this subtype PEARLY = 1.6E - 06, compared to features
selected based on GEP alone (PGEP = 1.0E - 05) or
DMP alone (PDMP = 1.5E - 04). Nevertheless, the clas-
sification accuracy was equal for all integration strate-
gies (F - score = 0.667).
In terms of number of features selected by the classi-
fier, we can read from Figure 1D (and Additional file 1:
Table S1) that a similar number is selected when trained
Figure 1 Classification performance for different integration strategies. A) Classification accuracy based on the DLCV scheme (F-score), B)
Classification performance based on the DLCV scheme (AUC). C) Resulting -log10(P-values) of global test based on the training and test sets. D)
Number of features extracted by logistic regression model from training subsets. Note that the late integration is based on the extracted features
from solely GEP and DMP.
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on the GEP and DMP separately. Moreover, the propor-
tions between GEP and DMP features are approximately
the same over the subtypes (r = 0.91). Interestingly, the
selected features obtained with the early integration
strategy are composed of both GEP and DMP features
(Figure 1D, green line). Strikingly, their proportions are
also similar (r = 0.92).
To summarize, an early integration strategy can improve
subtype classification. However, for some subtypes the
classification performance is equal to that obtained using
GEP or DMP alone. The latter observation may be
explained because no complementary information is car-
ried in the DNA-methylation and gene expression profiles
for certain subtypes. If this is the case, early integration
may even result in loss of performance as the dimensional-
ity of the original feature space approximately doubles in
size. As a result, classification will suffer more from the
small sample size problem.
Late integration demonstrates best classification accuracy
The best subtype classification accuracy was obtained by
a late integration strategy. It outperformed GEP, DMP
and early integration for all AML subtypes with one
exception; patients with t(15;17) showed better accuracy
in the early integration (F - score = 0.8) compared to the
late integration (F - score = 0.77). The better accuracy of
the late integration can be explained in two ways: first,
in the early integration strategy we standardized all fea-
tures to the same scale to make them equally important,
whereas in the late integration no additional normaliza-
tion is required for GEP and DMP as we train the 2nd
layer classifier on the outputs of the GEP and DMP
regressors. Secondly, the threshold on the posterior
probability is not fixed in the late integration scheme
but learned by the nearest mean classifier (NMC). The
latter is illustrated in Figure 2, where circles illustrate
samples for which the late integration makes a difference
between correct (in late integration) or wrong (in sepa-
rate) classification. A clear example is given by the set of
7q patients (Figure 2A) that improved in the classification
accuracy and performance (AUC = 0.799, F - score =
0.68) compared to GEP (AUC = 0.794, F - score = 0.56),
DMP (AUC = 0.733, F - score = 0.18) individually or early
integration (AUC = 0.799, F - score = 0.51) (Figure 1A
and 1B). Other sets of samples with a marked difference
are the NPM1mutant and FLT3ITD/NPM1wt patients as
shown in Figure 2B and 2C respectively.
Interestingly, the late integration approach is also
effective in cases where one of the data types was not
significantly associated with the subtype, such as for
cases with FLT3ITD/NPM1wt (PGEP = 0.0284 and PDMP =
0.057, Figure 1C). In this case the classification accuracy
was increased from 0.39 by using GEP to 0.52 using late
integration (Figure 1A and 2C).
Conclusions
In this study we demonstrate that integration of gene
expression and DNAmethylation profiles can improve the
classification performance. We show this by using an
AML dataset that contains 15 well-characterized cytogene-
tical and molecular subtypes. These results show that both
data types are synergistic, meaning that complementary
patterns are present in both data types that lead to a better
prediction of the leukemia subtypes. Although we demon-
strate improved predictive power by using early and late
integration, some subtypes only showed small improve-
ments, such as for the AML patients with favourable risk,
i.e. t(8;21), t(15;17) or inv(16). Nevertheless, the global test
showed in these subtypes that the features in an early inte-
gration strategy were more indicative for the subtype com-
pared to DMP, underpinning the observation that gene
expression and methylation are complementary measure-
ments when subtyping leukemia patients.
Patients with NRAS, FLT3TKD, 3q, 7q and 11q23
abnormalities showed improved prediction using the
late integration strategy but nevertheless, remain diffi-
cult to predict and therefore still require alternative
methods. This may be due to the high variability of
expression or methylation profiles within the subtype,
consequently features based on GEP or DMP cannot
accurately characterize the subtype. In fact, the test sta-
tistic from the global test indeed indicates no significant
association with 3q and 7q patients by using the features
from either the GEP (P = 0.122 and P = 0.051 respec-
tively) or DMP (P = 0.173 and P = 0.06 respectively).
Perhaps for these cases, a multitude of other comple-
mentary data sets, such as microRNA, Copy Number
Variation (CNV) or pathway information, is necessary to
delineate these subtypes.
In this study we have chosen to build a classifier that
is optimized for predictive power and the derived signa-
tures may therefore not be appropriate to study the bio-
logical effect. We demonstrate a supervised approach
that can improve the predictive power for each cytoge-
netic and molecular abnormality by employing an early
or late integration strategy, whereas the late integration
strategy is recommended above early integration.
Material and methods
AML dataset
For 344 adults, clinical, cytogenetical and molecular
characteristics were analysed using bone marrow or per-
ipheral blood, as described previously [3,9]. For each
patient sample, genome-wide mRNA expression data
(GEP) is measured using Affymetrix HGU133 plus2.0
(Santa Clara, CA, USA). Normalization of raw data was
processed with RMA [21-23] and probes on the array
are remapped to refseq transcripts using a custom chip
definition file (CDF) [24] (NGEP = 21678 refseqs). For
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the same set of samples, genome-wide DNA-methylation
data (DMP) was measured with the HELP-assay [25]
and pre-processed as described previously [9] (NDMP =
22725 features). Both datasets are annotated using
UCSC hg19 genome build, and are available from the
NCBI Gene Expression Omnibus accession numbers
GSE14468 (HOVON-SAKK cohort) and GSE18700,
respectively.
Cytogenetical and molecular abnormalities in AML
Groups of AML patients that are characterized by com-
mon cytogenetic or molecular abnormality are denoted
as subtypes. We studied fifteen of the most common
subtypes, which can roughly be categorized into three
risk groups (good, intermediate and poor). AML sub-
types in the good risk group are inv(16), t(15;17), t
(8;21). The intermediate risk group contains patients
with molecular abnormalities, i.e. CEBPAdouble-mutant,
CEBPAsilenced, NPM1mutant, FLT3ITD , FLT3TKD,
FLT3ITD/NPM1wt, FLT3 /NPM1mutant, FLT3ITD/
NPM1mutant, and NRAS cases. The poor risk group con-
tains patients with complex karyotype (patients with
more than 3 cytogenetic abnormalities), i.e. 3q, 7q, and
11q23 cases. We used the 15 subtypes as classification
labels. Note that samples can contain multiple
abnormalities.
Classification strategies
The AML subtypes are classified using three different
strategies: i) no integration using the GEP or DMP-data-
set individually); ii) early integration; and iii) late inte-
gration (Figure 3). For each subtype, we train a two
class classifier to distinguish between samples that
belong to the subtype and samples that belong to the
other 14 subtypes (i.e., one versus all classification
scheme). We employed the logistic regression classifier
with lasso regularization [26,27], which optimizes the
regression output and selects features by enforcing spar-
sity. To assure unbiased measurements of the perfor-
mance of the classifier we followed the double-loop
crossvalidation protocol (DLCV) [28]. First, we split the
input set into five equal subsets (the outer loop). For
each iteration we use one subset as validation set and
the other four subsets as input set for classifier training.
Training of the classifier is based on a 5-fold cross-vali-
dation scheme (the inner loop) to optimize the regres-
sion model parameters (see Figure 3 for more details).
To make sure that each feature is penalized similarly by
Figure 2 Classification results on the validation sets and their corresponding ROC curves. Top illustrates scatter plots of the logistic
regression classifier (first layer) outcomes on a validation subset for subtype (A) 7q (subset5), (B) NPM1mutant (subset2), and (C) FLT3ITD/NPM1wt
(subset3). Red and blue solid lines indicate the classification boundaries of the first layer (GEP and DMP respectively). The purple solid line
indicates the classification boundary of the second layer. Black encapsulated circles indicates samples that are misclassified when we trained the
first layer on GEP or DMP only. These are however correctly classified when we incorporate the the second layer. Bottom illustrates the ROC
curves of the scatter plots.
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lasso regressor, we standardized each feature to its unit
second central moment before applying penalization.
i No integration
For the GEP and the DMP input datasets we followed the
DLCV scheme, for each of the datasets separately. The
optimal set of features, i.e. those discriminating between
patients from one subtype and the remaining patients, were
determined in the DLCV inner loop. Subsequently, we used
this set of features to classify samples in the independent
validation set (DLCV outer loop) and then calculate the
classification performance and accuracy for each data type.
ii Early integration
In this strategy, we combined all the features by conca-
tenating the GEP and DMP features yielding NTOTAL =
44403 features. Then, we followed the DLCV scheme,
with the exception that we now provided the regression
model with all features.
iii Late integration
For the late integration strategy, we established a two-
layer classifier (Figure 3). Initially, we followed the
DLCV scheme for each data type separately. Each inner
loop generates two optimized sets of parameters for the
logistic regression model, one set for each data type. In
the next step we train an additional classifier, nearest
mean classifier (NMC), that uses the posterior probabil-
ities of the GEP and DMP logistic regressors as feature
space. Hence, the integration of the two data types is
achieved by exploiting the confidence with each indivi-
dual data type. Finally the output of the NMC is evalu-
ated on the validation set.
Classification accuracy and performance
F-score
The F-score is used to test the prediction accuracy,
which considers both the positive predictive value (pre-
cision) and the true positive rate (recall or sensitivity),
and varies between 0 (worst accuracy) to 1 (best accu-
racy). To assign a sample to a class, we used the default
threshold of 0.5 on the posterior probability obtained
from the logistic regressor. As a result, samples for
which the posterior probability is between 0.5 and 1.0
are assigned to the subtype of interest. The F-score is
especially of interest in diagnostic settings where it is
important to know how many patients (samples) are
correctly or wrongly classified.
Area under the curve (AUC)
The Area under the curve (AUC) is computed on the
Receiver Operator Characteristics (ROC), which integrates
Figure 3 Schematic overview of classification approach along with integration strategies. The left part shows no and early integration
strategies by training the logistic regression classifier on only GEP or DMP and GEP+DMP, respectively. In the DLCV scheme we split the input
data into five subsets. The classifier was trained by means of a 5-fold cross-validation approach using four subsets for training and testing and
one for validation. The right part shows the late integration procedure where the nearest mean classifier (NMC) (i.e. second layer) was trained on
the new two-dimensional data which represents the first layer outcomes for GEP and DMP sets. The second layer was evaluated by the first layer
outcomes of the validation subset. The reported performance is the average of classification performance on the 5 validation subsets.
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performance scores over all possible thresholds on the
posterior probability obtained from the regressor. This
effectively considers all possible assignments of samples to
the subtype by the regressor.
Global test
To examine whether the global pattern of an input set
significantly associates with the subtype, we apply the
global test method [29]. The use of the global test in the
evaluation is important beacuse the classification accu-
racy (F-score) and the classification performance (AUC)
describe only the classifier output scores on the test set.
The global test on the other hand results in a P-value
based on the null hypothesis that there is no information
in the given input features related to the sample label
(e.g. subtype). In fact, the global test method applies a
regression model to test the null hypotheses that the var-
iance of regression coefficients of all input features is
zero and subsequently calculates a test statistics.
Additional material
Additional file 1: Table S1. Table containing the classification
performance for different integration strategies.
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